PET-MRI Imaging in Patients With Acute Neurovascular Syndrome

Sponsor
University of Edinburgh (Other)
Overall Status
Completed
CT.gov ID
NCT03215563
Collaborator
(none)
80
1
26.9
3

Study Details

Study Description

Brief Summary

Ischaemic stroke is a major cause of death and disability worldwide. In patients with recent stroke, the 18F-fluoride positron emission tomography-computed tomography highlights high-risk culprit carotid plaque and is more discriminatory than 18F-fluorodeoxyglucose. Using hybrid positron emission tomography-magnetic resonance imaging investigators propose to build upon these findings by prospectively assessing 18F-fluoride uptake in a broad range of patients with acute transient ischaemic attack or ischaemic stroke. Investigators will specifically examine the association of 18F-fluoride uptake with multiparametric magnetic resonance imaging assessments of atherosclerotic plaque, especially the role of thrombus and lipid. Finally, using transcranial Doppler and diffusion-weighted magnetic resonance brain imaging, an assessment of the functional consequences of 18F-fluoride-positive atherosclerotic plaque will be performed. If successful, this technique has a number of valuable translational applications including the better selection of patients for carotid intervention.

Condition or Disease Intervention/Treatment Phase
  • Radiation: 18F PET-MRI
  • Diagnostic Test: Transcranial Doppler

Detailed Description

The ability to identify the culprit carotid plaque represents a key goal in carotid artery imaging. Although an array of non-invasive imaging techniques can detect a wide spectrum of complementary high-risk characteristics, no single modality can reliably identify vulnerable plaques associated with future stroke development. Substantial histological data suggests that specific plaque components identify patients at high-risk for future ipsilateral stroke and cardiovascular events. This implies that investigators need to look beyond the traditional paradigm where the basis for carotid endarterectomy were formulated by an invasive imaging modality that provided no information on the arterial wall composition. Alternative imaging strategies are therefore required targeting not only in vivo carotid morphology but also plaque biology and disease activity. This is fundamental to optimal risk-stratification and appropriate selection of patients for high-risk vascular intervention. One new approach is to use non-invasive molecular imaging targeted at plaque biology using hybrid systems such as positron emission tomography-magnetic resonance imaging.

Study Design

Study Type:
Observational
Actual Enrollment :
80 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Hybrid 18F-Fluoride Positron Emission Tomography-Magnetic Resonance Imaging in Patients With Acute Acute Neurovascular Syndrome
Actual Study Start Date :
Oct 12, 2017
Actual Primary Completion Date :
Jan 10, 2020
Actual Study Completion Date :
Jan 10, 2020

Arms and Interventions

Arm Intervention/Treatment
Carotid

Patients with carotid artery stenosis who either do not meet surgical criteria (< 50% by NASCET criteria for men, <70% for women), or meet criteria but do not undergo surgery (surgery declined or not offered) and are currently treated with OMT. This cohort will be recruited from the acute TIA clinics and Vascular Laboratory logbooks at Edinburgh Royal Infirmary and Western General Hospital.

Radiation: 18F PET-MRI
18F-fluoride Hybrid PET-MRI

Diagnostic Test: Transcranial Doppler
Microembolic Signals detection

Non Carotid

Patients with an atherosclerotic disease in the aortic arch including origins of its major branches other than the internal carotid artery treated with OMT. Patients with a cardiac source of embolism will be excluded from the study. This group will be recruited from the acute TIA clinics and inpatients at Edinburgh Royal Infirmary and Western General Hospital.

Radiation: 18F PET-MRI
18F-fluoride Hybrid PET-MRI

Diagnostic Test: Transcranial Doppler
Microembolic Signals detection

Outcome Measures

Primary Outcome Measures

  1. 18F-fluoride uptake in the culprit plaque in carotid, aortic and intra-cranial vessels. [2 weeks]

    18F-fluoride uptake will be measured by the mean and max Standardised Uptake Values (SUV) derived from the culprit atherosclerotic plaques.

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Patients above 40 years of age with carotid artery stenosis that do not achieve criteria for CEA (<50% for men, <70% for women, by NASCET criteria) or the patient has declined CEA.

  2. Patients above 40 years of age with atherosclerotic disease of aortic arch and its branches.

Exclusion Criteria:
  1. Patients with new stroke and a modified Rankin score >3

  2. Chronic kidney disease with an estimated Glomerular Filtration Rate (eGFR) of <30 ml/min/1.73 m2

  3. Atrial fibrillation

  4. Pregnant women

  5. Prior ipsilateral carotid intervention

  6. Prior neck radiotherapy

  7. Inability to tolerate the supine position

  8. Participation in the study would result in delay to surgery

  9. Psychiatric illness/social situations that would limit compliance with study requirements

  10. History of allergic reaction attributed to 18F-Fluoride

  11. History of allergic reaction to gadolinium contrast media

  12. Metal implants or devices including pacemakers and defibrillators

Contacts and Locations

Locations

Site City State Country Postal Code
1 Centre for Cardiovascular Science Edinburgh United Kingdom EH16 4SB

Sponsors and Collaborators

  • University of Edinburgh

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Edinburgh
ClinicalTrials.gov Identifier:
NCT03215563
Other Study ID Numbers:
  • AC17058
First Posted:
Jul 12, 2017
Last Update Posted:
Feb 11, 2020
Last Verified:
Feb 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University of Edinburgh
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 11, 2020